Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine. The multi-site research ...
Feb 21, 2014
0
0
Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group determined that adding bevacizumab to initial treatment for glioblastoma did not improve patient overall survival or progression-free ...
Feb 19, 2014
0
0
(Medical Xpress)—An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of ...
Jan 15, 2014
0
0
A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by ...
Oct 28, 2013
0
0
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease ...
Aug 19, 2013
0
0
A new cervical cancer drug offers the first good hope of extending life for women with advanced stages of the disease, according to a study published Sunday.
Jun 2, 2013
0
0
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research ...
Jun 2, 2013
0
0
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin), according to new research from The University of Texas MD Anderson Cancer Center.
Jun 2, 2013
0
0
A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released Saturday found.
Jun 1, 2013
0
1
Many glioblastoma patients treated with bevacizumab (Avastin) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according ...
Jun 1, 2013
0
0
